EXCLUSIVE: Antibody-Discovery Platform Provider ImmunoPrecise's Subsidiary Highlights Approach to Biological Sequence Retrieval

ImmunoPrecise Antibodies Ltd's IPA subsidiary BioStrand has published a preprint of its white paper titled "New Paradigm for Biological Sequence Retrieval Inspired by Natural Language Processing and Database Research" on biorxiv.org.

The publication delves into the intricacies of the HYFT-based methodology, a novel approach to biological sequence retrieval.

Key Highlights from the White Paper:

  • The paper introduces HYFT patterns as unique signature sequences, akin to biological fingerprints, found in amino acids, DNA, and RNA. These patterns serve as a tool to tokenize all biological data into a unified omics language.
  • The paper details the two-step process of parsing biological sequences to retrieve HYFT patterns and then indexing them. This approach prioritizes non-overlapping HYFTs with lower ranks, ensuring comprehensive sequence coverage.
  • A comparative study between BLAST and the HYFT methodology revealed that while BLAST excels in retrieving distant homologous sequences, HYFT is particularly relevant for higher identity matches.

BioStrand has rolled out a next-generation unified knowledge graph-LLM framework.

At the core of their LENSai platform is a comprehensive and continuously expanding knowledge graph that maps 25 billion relationships across 660 million data objects, linking sequence, structure, function, and literature information.

Price Action: IPA shares closed at $1.56 on Friday.

Market News and Data brought to you by Benzinga APIs
Posted In: NewsPenny StocksHealth CareMarket-Moving ExclusivesExclusivesGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...